Batch 001 samples are currently in third-party testing. This product is gated and will not be released until testing is complete and approved.
CJC-1295 (NO DAC), commonly referred to as Modified GRF(1-29), is a 29-amino-acid analog of the active N-terminal fragment of human growth hormone-releasing hormone (GHRH). It is used in laboratory research focused on GHRH receptor signaling, GH-axis pulsatility, and comparisons between short-acting and albumin-binding GHRH analogs.
DAC vs. NO DAC — what changes?
DAC stands for Drug Affinity Complex. In CJC-1295 DAC, an albumin-binding maleimide group is added so the peptide can associate with serum albumin and remain in circulation much longer. NO DAC means that albumin-binding group is absent. The no-DAC form is therefore studied as a shorter-acting, more pulse-like GHRH analog, while the DAC form is studied for sustained exposure over a multi-day window.
Research compound — for laboratory use only.
CJC-1295 (NO DAC)
Modified GHRH(1-29) Without Drug Affinity Complex — For Research Use Only
Product Details
- Strength: 5mg
- Batch: B001
- Inventory: 40 vials on hand, gated pending testing
- Form: Lyophilized powder
- Testing: Batch 001 COA in progress
- Status: Not available for purchase until testing is complete and approved
Compound Reference
- Synonyms: Modified GRF(1-29), Mod GRF 1-29, CJC-1295 without DAC
- CAS: 446036-97-1
- Molecular Formula: C152H252N44O42
- Molecular Weight: 3367.9 g/mol
- Research target: GHRH receptor (GHRHR) on anterior pituitary somatotrophs
Storage
Store lyophilized powder frozen (-20°C) for long-term storage. After reconstitution, refrigerate (2–8°C) and use within 30 days.
FOR RESEARCH USE ONLY — NOT FOR HUMAN CONSUMPTION
